Risk reduction for stroke and coronary events.
Mazouz
Hakim
H
Makdassi
Raifah
R
Tribouilloy
Christophe
C
Choukroun
Gabriel
G
Andrejak
Michel
M
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001581:Benzothiadiazines; D002986:Clinical Trials as Topic / Q000379:methods*; D004232:Diuretics; D006801:Humans; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D020521:Stroke / Q000517:prevention & control*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors